Page 1 of 2
Sort by: Relevance | Date
This article is part of a Supplement: Volume 18 Supplement 1
The Correction to this article has been published in Trials 2018 19:99
This article is part of a Supplement: Volume 20 Supplement 1
Multi-arm trials enable the evaluation of multiple treatments within a single trial. They provide a way of substantially increasing the efficiency of the clinical development process. However, since multi-arm ...
Platform trials improve the efficiency of the drug development process through flexible features such as adding and dropping arms as evidence emerges. The benefits and practical challenges of implementing nove...
The editors of BMC Medical Research Methodology would like to thank all our reviewers who have contributed to the journal in Volume 15 (2015).
Despite progress that has been made in the treatment of many immune-mediated inflammatory diseases (IMIDs), there remains a need for improved treatments. Randomised controlled trials (RCTs) provide the highest...
This article is part of a Supplement: Volume 14 Supplement 1
This article is part of a Supplement: Volume 14 Supplement 1
This article is part of a Supplement: Volume 14 Supplement 1
Clinical trials and other studies commonly assess the effectiveness of an intervention through the use of responder-based endpoints. These classify patients based on whether they meet a number of criteria whic...
This article is part of a Supplement: Volume 23 Supplement 1
Composite responder endpoints feature frequently in rheumatology due to the multifaceted nature of many of these conditions. Current analysis methods used to analyse these endpoints discard much of the data us...
A peer-reviewed journal would not survive without the generous time and insightful comments of the reviewers, whose efforts often go unrecognized. Although final decisions are always editorial, they are greatl...
The primary objective of MATIS is to determine the efficacy of ruxolitinib (RUX) or fostamatinib (FOS) compared to standard of care (SOC) with respect to reducing the proportion of hospitalised patients progre...
Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. ...
In the UK, the Medicines and Healthcare products Regulatory Agency consulted on proposals “to improve and strengthen the UK clinical trials legislation to help us make the UK the best place to research and dev...
The Correction to this article has been published in Trials 2023 24:744
This article is part of a Supplement: Volume 11 Supplement 1
This article is part of a Supplement: Volume 20 Supplement 1
Adaptive designs are a class of methods for improving efficiency and patient benefit of clinical trials. Although their use has increased in recent years, research suggests they are not used in many situations...
Genome-wide association studies (GWAS) are a widely used study design for detecting genetic causes of complex diseases. Current studies provide good coverage of common causal SNPs, but not rare ones. A popular...